Biohybrid magnetic carrier robots for targeted bacteria release in ulcerative colitis
Abstract
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by persistent inflammation and ulcers in the colon and rectum. Notably, UC is commonly associated with microbial dysbiosis while bacterial therapies often fail to achieve durable, site-specific colonization. Here, we develop a biohybrid magnetic carrier robot (MCR) platform that delivers bacteria along programmed trajectories and enables prolonged retention at target sites. The MCR is structured with a thin layer of hard-magnetic soft material that responds sensitively to magnetic fields, and a functional layer of bacteria-loaded hydrogel that preserves bacterial viability and release probiotics at specific pH values. This multi-material system is created via a multi-layer screen-printing technique, which allows precise patterning of functional materials at the submillimeter scale and holds promise for scalable production. Precise wireless navigation is validated in simulated environments using a robotic-arm-assisted magnetic driving system. In vivo studies in mice show that MCR-assisted treatment accelerates clinical recovery, significantly increases gut microbial diversity, and mitigates colon damage. In a DSS-induced acute colitis mouse model, the biohybrid magnetic carrier robots improved body-weight recovery, disease activity, colon length, and histological morphology relative to the disease model and material-only controls, while several outcomes also improved relative to free bacteria-loaded…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.